-
Straumann Group reports 12% organic revenue growth in the third quarter of 2022
Third-quarter revenue amounts to CHF 551 million, an increase of 12%, bringing revenue in the first nine months of 2022 to CHF 1.7 billion All regions performing well with LATAM leading organic growth with 21% Roxolid SLActive study highlights preclinical premium implant outcome ClearCorrect received regulatory approval in China Investment in SmileCloud, a smile design and collaboration platform Full-year 2022 outlook raised to organic revenue growth expected in the mid-teens percentage range and profitability at around 26% including significant growth investments Straumann Group achieved revenue of CHF 551 million in the third quarter of 2022 which is traditionally softer than the first two quarters due to the summer vacations in…
-
Straumann Group reports very strong first quarter
. Quarterly revenue of CHF 589 million, 27.2% organic revenue growth on previous year Strong organic double-digit growth in all regions; LATAM fastest-growing Launch of two innovative challenger brand implants, Neodent Zi and Anthogyr X3 Acquisition of a strategic minority stake in CareStack, a cloud-based practice management software Outlook for 2022 confirmed: Organic revenue growth expected in the low double-digit percentage range and profitability is expected around 26% including major growth investments Straumann Group made a strong start to 2022. Revenue in the first quarter reached CHF 589 million and organic growth was 27.2% compared to the same quarter in 2021, which did not see a negative effect due to…
-
Straumann Group announces new Executive Management Board members to support growth strategy
Jason Forbes joins as Straumann Group Chief Consumer Officer, a newly created position in the Executive Management Board Sébastien Roche appointed as Chief Operations and Supply Chain Officer Changes are designed to achieve ambitious growth in line with the company’s emphasis on digital transformation and aspiration to build a consumer presence New leadership roles will bring in decades of work experience and diverse work portfolios from different industries Today Straumann Group announced Executive Management Board (EMB) changes which will ensure the structure of its leadership team is mirroring and supporting the Group’s growth strategy. These announcements follow the evolved strategic compass which was presented in December 2021. Jason Forbes…
-
Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
Ambition to achieve CHF 5 billion revenue by 2030 considering an average organic growth rate of at least 10%, core EBIT margin expected to range between 25-30% in the next years depending on investment, and on continuous increase of gross dividend Culture remains a key pillar with an employee engagement score of 80 in 2021 – in the top 25% of companies Core implantology business strongly positioned to grow from 29% market share across premium and value segments through innovation and geographic expansion respectively Orthodontics business set to grow via sharpening its value proposition development, expanding geographical presence and driving complementary business models Digital transformation to shape new pathways…
-
Straumann Group Capital Markets Day 2021
Straumann Group invites you to attend our Capital Markets Day 2021 on Thursday, December 16, 2021. Due to the uncertainty and travel restrictions related to the COVID-19 pandemic, it will be held in a virtual format only. The Group is evolving from an implant to an oral care company. At the Capital Markets Day, we will provide more details about our strategy for the coming years and will reflect on the current trends. All information will be presented by our executive management team. The live audio webcast is aimed at investors, financial analysts and journalists. The presentation and Q&A session will be in English. The webcast can be accessed via www.straumann-group.com/webcast and a recording will be made…
-
Straumann Group further accelerates growth in the second quarter to deliver record first half-year result
Half-year revenue reached CHF 986 million or 63% organic growth Revenue increased by 103% to reach CHF 516 million in the second quarter, with all regions reporting impressive sales growth Strong volume growth brought core EBIT to CHF 284 million, with a margin of 29% Reported net profit rose to CHF 175 million or 18%, including DrSmile earn-out adjustment Acquisition of Smilink, a doctor-led direct-to-consumer business, further strengthens the orthodontics business in Brazil Full-year 2021 outlook raised to organic revenue growth of above thirty percent, with profitability (core EBIT margin) nearly reaching the 2019 level, assuming the pandemic does not negatively impact the patient flow Straumann Group revenue reached CHF…
